Evidence map›Paper›PMID 35409350›Full record

ArticleInternational journal of molecular sciences2022

Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells.

Yu-Hsuan Kuo, Yi-Xuan Wang, Wan-Hua Peng, Nian-Yu Chi, Tzong-Huei Lee, Chi-Chung Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-Hsuan KuoDepartment of Oncology, Chi-Mei Hospital, Tainan 710402, Taiwan.
Yi-Xuan WangGraduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City 242062, Taiwan.
Wan-Hua PengGraduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City 242062, Taiwan.
Nian-Yu ChiGraduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City 242062, Taiwan.
Tzong-Huei LeeInstitute of Fisheries Science, National Taiwan University, Taipei 106319, Taiwan.ORCID 0000-0001-8036-7563
Chi-Chung WangGraduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City 242062, Taiwan.

Funding

Chi-Mei Hospital CMFJ10204Ministry of Science and Technology, Taiwan MOST 105-2320-B-030-006Ministry of Science and Technology, Taiwan MOST 107-2314-B-030-010-MY2
6 · The paper itself

Abstract

Both in Taiwan and around the world, lung cancer is a primary cause of cancer-related deaths. In Taiwan, the most prevalent form of lung cancer is lung adenocarcinoma, a type of non-small-cell lung carcinoma. Although numerous lung cancer therapies are available, their clinical outcomes are unsatisfactory. Natural products, including fungal metabolites, are excellent sources of pharmaceutical compounds used in cancer treatment. We employed in vitro cell invasion, cell proliferation, cell migration, cell viability, and colony formation assays with the aim of evaluating the effects of coriloxin, isolated from fermented broths of

Indexed as

Adenocarcinoma of LungAntineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsA549 CellsCell Line, TumorHumansAntineoplastic Agentsanticancercoriloxinlung adenocarcinomanatural product

Identifiers

PMID35409350
PMCPMC8999459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.